Janus Henderson Group PLC Raises Stock Position in MoonLake Immunotherapeutics $MLTX

Janus Henderson Group PLC increased its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 64.7% in the 1st quarter, HoldingsChannel reports. The fund owned 3,451,628 shares of the company’s stock after acquiring an additional 1,355,640 shares during the period. Janus Henderson Group PLC’s holdings in MoonLake Immunotherapeutics were worth $64,304,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in MoonLake Immunotherapeutics by 221.1% in the first quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock valued at $53,000 after acquiring an additional 1,974 shares in the last quarter. Readystate Asset Management LP acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth $2,689,000. Exome Asset Management LLC acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth $4,015,000. The Manufacturers Life Insurance Company lifted its holdings in shares of MoonLake Immunotherapeutics by 39.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 118,961 shares of the company’s stock valued at $2,217,000 after purchasing an additional 33,391 shares during the last quarter. Finally, Weiss Asset Management LP lifted its holdings in shares of MoonLake Immunotherapeutics by 413.1% during the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock valued at $31,843,000 after purchasing an additional 1,375,367 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Trading Down 2.9%

NASDAQ:MLTX opened at $18.44 on Friday. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The firm has a fifty day simple moving average of $19.12 and a 200-day simple moving average of $17.85. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $1.36 billion, a P/E ratio of -4.76 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). On average, equities research analysts anticipate that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current year.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $20.02, for a total transaction of $1,001,000.00. Following the sale, the insider owned 2,714,746 shares in the company, valued at approximately $54,349,214.92. The trade was a 1.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $20.02, for a total value of $1,367,145.78. Following the completion of the transaction, the chief executive officer directly owned 2,774,893 shares in the company, valued at $55,553,357.86. This represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 344,800 shares of company stock valued at $6,820,071. 10.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

MLTX has been the topic of several research analyst reports. Needham & Company LLC boosted their target price on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of MoonLake Immunotherapeutics in a research note on Monday, July 20th. Finally, Leerink Partners boosted their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of “Hold” and an average target price of $24.21.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.